Ifebemtinib

N/A

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameIfebemtinib
Drug Alias NameifebeIN-10018BI-853520
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFocal adhesion kinase 1 inhibitorsFocal adhesion kinase inhibitors
TargetsFocal adhesion kinase 1Focal adhesion kinase
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[16] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesTaiwan +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBoehringer Ingelheim Corp
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesYingshi Biotechnology (Shenzhen) Co LtdWuhan Union HospitalZhejiang Hangyu Pharmaceutical Co Ltd +[5] 
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursUterine Cervical Neoplasms +[14] 
Inactive IndicationsEsophageal NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A